The team will develop next-generation computational models that incorporate two key factors that are often overlooked in understanding how proteins function and dysfunction in disease: small molecules found in the body (metabolites) and cell membranes and similar surfaces (lipid interfaces). The goal is to establish these as first-class variables to accurately predict IDP aggregation across healthy and disease conditions. These include neurodegenerative diseases, diabetes, and cancer which are linked to membrane trafficking dysfunction (cell’s delivery system is not working correctly).